Update to: The Aryl Hydrocarbon Receptor in Anticancer Drug Discovery: Friend or Foe?

Major advances in our understanding of the mechanistic features and regulation of Aryl hydrocarbon Receptor (AhR) mediated signal transduction have been made in recent years. This review updates our previously published article “The Aryl Hydrocarbon Receptor in Anticancer Drug Discovery: Friend or Foe” (Current Pharmaceutical Design, 2002, 8, 2475-2490), focussing on the most recent developments in the field. Discussion of receptor regulation and crosstalk, structural studies on the ligand binding domain, the search for endogenous ligands, and therapeutic possibilities in the cancer field associated with AhR ligands, feature prominently here.